Related Experiment Video

Updated: Mar 26, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.4K

Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy

Federica Biello1, Giovanni Burrafato, Erika Rijavec

  • 1UOS Tumori Polmonari, IRCCS AOU San Martino IST- Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi n°10, 16132 Genova, Italy. febiello@gmail.com.

Anti-Cancer Agents in Medicinal Chemistry
|February 5, 2016
PubMed

Insights

Fibroblast growth factor receptor (FGFR) plays a key role in non-small cell lung cancer (NSCLC). Research reviews FGFR aberrations and targeted therapies, but their effectiveness and FGFR

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Lung cancer remains a leading cause of cancer mortality globally.
  • Fibroblast growth factor receptor (FGFR) pathway dysregulation, via amplification or mutation, is implicated in non-small cell lung cancer (NSCLC) development.
  • FGFR alterations are particularly noted in squamous cell carcinomas, a subtype of NSCLC.

Purpose of the Study:

  • To review the current literature on the Fibroblast growth factor (FGF)-FGFR pathway in NSCLC.
  • To evaluate the prognostic role of FGFR aberrations in NSCLC, especially squamous cell carcinomas.
  • To assess the status and challenges of novel FGFR-targeted therapies in NSCLC.

Main Methods:

  • Comprehensive literature review of existing studies on FGFR in NSCLC.
  • Analysis of the FGF-FGFR pathway and its aberrations.
  • Evaluation of potential prognostic significance and therapeutic targeting of FGFR.

Main Results:

  • FGFR amplification/mutation is linked to tumor development in NSCLC.
  • New FGFR inhibitors are under clinical evaluation, but their predictive biomarkers remain uncertain.
  • The role of FGFR as a therapeutic target in squamous cell histology is under scrutiny, with limited clinical data on efficacy and side effect management.

Conclusions:

  • FGFR pathway dysregulation is a significant factor in NSCLC, particularly squamous cell carcinoma.
  • While FGFR inhibitors represent a promising therapeutic avenue, their clinical effectiveness, predictive markers, and management of side effects require further investigation.
  • The precise role of FGFR as a target in specific NSCLC subtypes needs clarification.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
633
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
4.3K